Ajay K. Nooka

15.1k total citations · 1 hit paper
282 papers, 6.0k citations indexed

About

Ajay K. Nooka is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ajay K. Nooka has authored 282 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 231 papers in Hematology, 144 papers in Oncology and 128 papers in Molecular Biology. Recurrent topics in Ajay K. Nooka's work include Multiple Myeloma Research and Treatments (227 papers), Protein Degradation and Inhibitors (83 papers) and Cancer Treatment and Pharmacology (45 papers). Ajay K. Nooka is often cited by papers focused on Multiple Myeloma Research and Treatments (227 papers), Protein Degradation and Inhibitors (83 papers) and Cancer Treatment and Pharmacology (45 papers). Ajay K. Nooka collaborates with scholars based in United States, Spain and Canada. Ajay K. Nooka's co-authors include Sagar Lonial, Jonathan L. Kaufman, Lawrence Boise, María‐Victoria Mateos, Vikas A. Gupta, Katja Weisel, Xiang Qin, Andrew Spencer, Pieter Sonneveld and Vânia Hungria and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Ajay K. Nooka

251 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

2016 1.1k citations Katja Weisel, Ajay K. Nooka et al. profile →

Peers

Countries citing papers authored by Ajay K. Nooka

Since Specialization

Citations

This map shows the geographic impact of Ajay K. Nooka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ajay K. Nooka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ajay K. Nooka more than expected).

Fields of papers citing papers by Ajay K. Nooka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ajay K. Nooka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ajay K. Nooka. The network helps show where Ajay K. Nooka may publish in the future.

Co-authorship network of co-authors of Ajay K. Nooka

This figure shows the co-authorship network connecting the top 25 collaborators of Ajay K. Nooka. A scholar is included among the top collaborators of Ajay K. Nooka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ajay K. Nooka. Ajay K. Nooka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Ajai Chari, Susan Bal, Sikander Ailawadhi, Amrita Krishnan, Krina K. Patel, Jesús G. Berdeja, Alfred L. Garfall, Natalie S. Callander, Rahul Banerjee, Melissa Alsina, Ajay K. Nooka, Binod Dhakal, Cristina Gasparetto, Caitlin Costello	0
2	Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract 2025 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Danielle Roberts, Vikas A. Gupta, Nisha S. Joseph, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman	0
3	Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Cindy Varga, Myra Robinson, Vikas A. Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, (unknown), Christopher J. Ferreri, (unknown), Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph	0
4	Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis 2025 ·American Journal of Hematology ·Joshua Richter, Ajay K. Nooka, Paula Rodríguez‐Otero, Fredrik Schjesvold, Eirini Katodritou, (unknown), (unknown), Leanne Cooper, (unknown), Nick Ballew, (unknown), Natalie Boytsov, (unknown), Simon McNamara	1
5	Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity 2024 ·npj Vaccines ·Alberto Moreno, Kelly E. Manning, (unknown), Ajay K. Nooka, Madison Ellis, (unknown), Jeffrey M. Switchenko, Bushra Wali, Jonathan L. Kaufman, Craig C. Hofmeister, Nisha S. Joseph, Sagar Lonial, Kavita M. Dhodapkar, Madhav V. Dhodapkar, Mehul S. Suthar	0
6	Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study 2024 ·British Journal of Haematology ·Ajay K. Nooka, Jonathan L. Kaufman, César A. Rodríguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson	0
7	Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast 2023 ·The Oncologist ·(unknown), Jeffrey M. Switchenko, Madhusmita Behera, Mehmet Asım Bilen, Taofeek K. Owonikoko, Jonathan L. Kaufman, Ajay K. Nooka, Colleen M. Lewis, (unknown), (unknown), (unknown), Olatunji B. Alese, R. Donald Harvey, Jennifer W. Carlisle	0
8	Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study 2023 ·Cancer ·Ajay K. Nooka, Cesar Rodriguez, María‐Victoria Mateos, Salomon Manier, Katherine Chastain, Arnob Banerjee, Rachel Kobos, Keqin Qi, Raluca Verona, (unknown), Thomas G Martin, Niels W.C.J. van de Donk	36
9	Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma 2023 ·Cancer ·Thomas G Martin, María‐Victoria Mateos, Ajay K. Nooka, Arnob Banerjee, Rachel Kobos, Lixia Pei, Ming Qi, Raluca Verona, (unknown), Jennifer Smit, (unknown), Danielle Trancucci, Clarissa Uhlar, Niels W.C.J. van de Donk, Cesar Rodriguez	28
10	Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction 2023 ·JCO Oncology Practice ·(unknown), (unknown), (unknown), Yuan Liu, (unknown), Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, R. Donald Harvey	7
11	Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma 2022 ·Science Advances ·(unknown), Remya Nair, Abhinav Achreja, Anjali Mittal, Pulkit Gupta, (unknown), (unknown), Olamide Animasahun, Bhakti Dwivedi, Benjamin G. Barwick, Vikas A. Gupta, Shannon M. Matulis, Manoj Bhasin, Sagar Lonial, Ajay K. Nooka, Arun P. Wiita, Lawrence Boise, Deepak Nagrath, Mala Shanmugam	12
12	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia 2021 ·Blood Cancer Discovery ·Akhilesh Kaushal, Ajay K. Nooka, (unknown), Katherine E. Pendleton, Benjamin G. Barwick, (unknown), Samuel S. McCachren, Vikas A. Gupta, Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Leonard T. Heffner, Stephen M. Ansell, Lawrence Boise, Sagar Lonial, Kavita M. Dhodapkar, Madhav V. Dhodapkar	14
13	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma 2021 ·Clinical Cancer Research ·Benjamin G. Barwick, Vikas A. Gupta, Shannon M. Matulis, (unknown), Doris R. Powell, Yanyan Gu, David L. Jaye, Karen N. Conneely, Yin C. Lin, Craig C. Hofmeister, Ajay K. Nooka, Jonathan J. Keats, Sagar Lonial, Paula M. Vertino, Lawrence Boise	10
14	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma 2020 ·Journal of Clinical Oncology ·Nisha S. Joseph, Jonathan L. Kaufman, Madhav V. Dhodapkar, Craig C. Hofmeister, (unknown), Leonard T. Heffner, Vikas A. Gupta, Lawrence Boise, Sagar Lonial, Ajay K. Nooka	132
15	Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm) 2020 ·SHILAP Revista de lepidopterología ·Alice Annalisa Medaglia, Ajay K. Nooka, (unknown), Nizar J. Bahlis, Katja Weisel, Albert Oriol, Antonio A. Alonso, Attaya Suvannasankha, Beata Holkova, Katarina Luptakova, (unknown), Brandon E. Kremer, (unknown), (unknown), D. A. Smith, Roxanne C. Jewell, (unknown), Joanna Opalińska, Suzanne Trudel	1
16	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma 2020 ·Nature Communications ·Richa Bajpai, Aditi Sharma, Abhinav Achreja, (unknown), Changyong Wei, (unknown), Vikas A. Gupta, Shannon M. Matulis, Samuel K. McBrayer, Anjali Mittal, Manali Rupji, Benjamin G. Barwick, Sagar Lonial, Ajay K. Nooka, Lawrence Boise, Deepak Nagrath, Mala Shanmugam	76
17	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Jonathan L. Kaufman, Roberto Mina, Jatin J. Shah, Jacob P. Laubach, Ajay K. Nooka, Colleen Lewis, Charise Gleason, (unknown), R. Donald Harvey, Leonard T. Heffner, Paul G. Richardson, Sagar Lonial, Robert Z. Orlowski	5
18	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy 2019 ·JCI Insight ·Jithendra Kini Bailur, Samuel S. McCachren, Deon B. Doxie, Mahesh Shrestha, Katherine E. Pendleton, Ajay K. Nooka, Natalia Neparidze, Terri L. Parker, Noffar Bar, Jonathan L. Kaufman, Craig C. Hofmeister, Lawrence Boise, Sagar Lonial, Melissa L. Kemp, Kavita M. Dhodapkar, Madhav V. Dhodapkar	117
19	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents 2018 ·Cancer ·Roberto Mina, Nisha S. Joseph, Jonathan L. Kaufman, Vikas A. Gupta, Leonard T. Heffner, Craig C. Hofmeister, Lawrence Boise, Madhav V. Dhodapkar, Charise Gleason, Ajay K. Nooka, Sagar Lonial	34
20	Evaluating Risk Factors and Outcomes For Clostridium Difficile Infection (CDI) In Stem Cell Transplant (SCT) Recipients 2013 ·Blood ·Nishi Shah, Ajay K. Nooka, Jonathan L. Kaufman, (unknown), (unknown), (unknown), (unknown), Edmund K. Waller, Sagar Lonial, Amelia Langston	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact